FGF23 and chronic kidney disease: In randomized controlled trials conducted in patients with CKD, ferric citrate (FC) has been shown to control serum phosphate, improve iron status, and decrease circulating FGF23 concentrations2–6,26, with one small trial observing improved clinical outcomes with FC treatment26.